Literature DB >> 24996654

Awareness and coverage of mass drug administration for elimination of lymphatic filariasis: a community based cross sectional study in Nepal.

Ram Kumar Adhikari1, Jeevan Bahadur Sherchand, Shiva Raj Mishra, Kamal Ranabhat, Rajendra Raj Wagle.   

Abstract

Lymphatic filariasis (LF) is among the major public health problems in Nepal. The disease is a major cause of morbidities primarily, lymphedema of legs and hydrocele and it impedes socio economic development in many endemic areas of the country. This study is aimed at exploring the understanding of people about mass drug administration (MDA) of the said disease and the status of compliance of MDA in Nepal. This study is a cross sectional study carried out among 894 household samples in three of the sixty LF endemic districts. The selected districts were Dhading, Kapilvastu and Kailali. The sentinel surveillance of sites in three districts constituted the sampling frame at the first stage. The peripheral health care centers in the sentinel sites constituted the sampling frame at the second stage of sampling. The coverage of MDA was 95.5 %. However, the compliance was less. Only 71.6 % of the respondents who took the drugs from health workers swallowed the diethyl carbamazine (DEC) completely, other did not swallow. In the present study, majority of respondents reported that they had heard or seen persons with side effects of DEC in their community. A total of 20 % of respondents reported that they had side effects after having DEC and only 3.9 % of these side effects were treated. The Female Community Health volunteers (FCHVs), health workers and radio/Television (TV) were the chief sources of MDA related information. This study recommends for a concerted public health action combining effective drug delivery mechanism and sound public awareness campaigns. The community people need to be made aware beforehand about the location, time of drug distribution. Also public awareness of the DEC should be conducted so that people would trust it and comply with the drug regime. Along with the health workers and radio/TV that has been used traditionally, we recommend mobilization of FCHVs in the public awareness campaigns the MDA campaigns.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 24996654     DOI: 10.1007/s10900-014-9891-1

Source DB:  PubMed          Journal:  J Community Health        ISSN: 0094-5145


  14 in total

1.  Wolbachia bacteria of filarial nematodes: a target for control?

Authors:  M J Taylor; C Bandi; A M Hoerauf; J Lazdins
Journal:  Parasitol Today       Date:  2000-05

2.  Coverage, compliance and some operational issues of mass drug administration during the programme to eliminate lymphatic filariasis in Orissa, India.

Authors:  B V Babu; S K Kar
Journal:  Trop Med Int Health       Date:  2004-06       Impact factor: 2.622

3.  The female community health volunteer programme in Nepal: decision makers' perceptions of volunteerism, payment and other incentives.

Authors:  Claire Glenton; Inger B Scheel; Sabina Pradhan; Simon Lewin; Stephen Hodgins; Vijaya Shrestha
Journal:  Soc Sci Med       Date:  2010-03-16       Impact factor: 4.634

Review 4.  Achieving Millennium Development Goals 4 and 5 in Nepal.

Authors:  D S Malla; K Giri; C Karki; P Chaudhary
Journal:  BJOG       Date:  2011-09       Impact factor: 6.531

5.  Community-wide reduction in prevalence and intensity of intestinal helminths as a collateral benefit of lymphatic filariasis elimination programs.

Authors:  Madsen Beau De Rochars; Abdel N Direny; Jacquelin M Roberts; David G Addiss; Jeanne Radday; Michael J Beach; Thomas G Streit; Desire Dardith; Jack Guy Lafontant; Patrick J Lammie
Journal:  Am J Trop Med Hyg       Date:  2004-10       Impact factor: 2.345

6.  Informal consultation on preventing disability from lymphatic filariasis, WHO, Geneva, August 2006.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2006-10-06

7.  A controlled trial of ivermectin and diethylcarbamazine in lymphatic filariasis.

Authors:  E A Ottesen; V Vijayasekaran; V Kumaraswami; S V Perumal Pillai; A Sadanandam; S Frederick; R Prabhakar; S P Tripathy
Journal:  N Engl J Med       Date:  1990-04-19       Impact factor: 91.245

8.  Efficacy of single dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis.

Authors:  M M Ismail; R L Jayakody; G J Weil; N Nirmalan; K S Jayasinghe; W Abeyewickrema; M H Rezvi Sheriff; H N Rajaratnam; N Amarasekera; D C de Silva; M L Michalski; A S Dissanaike
Journal:  Trans R Soc Trop Med Hyg       Date:  1998 Jan-Feb       Impact factor: 2.184

9.  Impact of two rounds of mass drug administration using diethylcarbamazine combined with albendazole on the prevalence of Brugia timori and of intestinal helminths on Alor Island, Indonesia.

Authors:  Tim Oqueka; Taniawati Supali; Is Suhariah Ismid; Paul Rückert; Mark Bradley; Peter Fischer
Journal:  Filaria J       Date:  2005-07-13

10.  Mapping of lymphatic filariasis in Nepal.

Authors:  Jeevan B Sherchand; Valérie Obsomer; Garib Das Thakur; Marcel Hommel
Journal:  Filaria J       Date:  2003-03-19
View more
  5 in total

1.  Treatment Coverage Estimation for Mass Drug Administration for Malaria with Dihydroartemisinin-Piperaquine in Southern Province, Zambia.

Authors:  Timothy P Finn; Joshua O Yukich; Adam Bennett; Travis R Porter; Christopher Lungu; Busiku Hamainza; Elizabeth Chizema Kawesha; Ruben O Conner; Kafula Silumbe; Richard W Steketee; John M Miller; Joseph Keating; Thomas P Eisele
Journal:  Am J Trop Med Hyg       Date:  2020-08       Impact factor: 2.345

2.  Feasibility of school-based health education intervention to improve the compliance to mass drug administration for lymphatic Filariasis in Lalitpur district, Nepal: A mixed methods among students, teachers and health program manager.

Authors:  Prativa Karki; Yayi Suryo Prabandari; Ari Probandari; Megha Raj Banjara
Journal:  PLoS One       Date:  2018-09-14       Impact factor: 3.240

Review 3.  Genomic Epidemiology in Filarial Nematodes: Transforming the Basis for Elimination Program Decisions.

Authors:  Shannon M Hedtke; Annette C Kuesel; Katie E Crawford; Patricia M Graves; Michel Boussinesq; Colleen L Lau; Daniel A Boakye; Warwick N Grant
Journal:  Front Genet       Date:  2020-01-09       Impact factor: 4.599

4.  Public engagement during a typhoid conjugate vaccine trial in Lalitpur, Nepal- experience, challenges and lessons learnt.

Authors:  Ashata Dahal; Mila Shakya; Dikshya Pant; Anup Adhikari; Rachel Colin-Jones; Katherine Theiss-Nyland; Andrew J Pollard; Buddha Basnyat; Shrijana Shrestha
Journal:  Hum Vaccin Immunother       Date:  2022-03-03       Impact factor: 4.526

5.  Impact of mass drug administration for elimination of lymphatic filariasis in Nepal.

Authors:  Chet Raj Ojha; Basant Joshi; Khagendra Prakash Kc; Shyam Prakash Dumre; Keshav Kumar Yogi; Bandana Bhatta; Tulasi Adhikari; Kathryn Crowley; Babu Ram Marasini
Journal:  PLoS Negl Trop Dis       Date:  2017-07-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.